Amgen Faces a July 29 Deadline to Save Tavneos From an FDA Withdrawal. Here’s What It Means for the Stock.
A judge just saved Enbrel’s pricing. Tavneos heads to an FDA hearing on July 29. What happens to Amgen stock next?
Read the full articleYou might also wanna read
Amgen continues to defend Tavneos as global regulatory pressure mounts
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel
Regulators push Amgen to withdraw drug due to data manipulation
Questions raised over safety and efficacy of Tavneos (avacopan)
STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen
How Safe Is Amgen's Dividend?
Near-term headwinds could sink the stock, but there is more to the story.
FDA Sets Early 2027 Review Deadline for Sarepta’s Duchenne Exon-Skipping Therapies Despite Confirmatory Trial Setback
As reported on BioSpace, Sarepta Therapeutics has reached an important regulatory milestone in its effort to secure traditional FDA approval
Comments
Sign in to join the conversation.
No comments yet. Be the first.